Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast
August 01 2019 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will host a conference
call and live audio webcast at 10 a.m. EDT on August 8,
2019, to review the second quarter ended June 30, 2019,
financial results and provide a business update.
To access the live conference call by phone, dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13691544. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, http://ir.albireopharma.com/. To
ensure a timely connection to the webcast, it is recommended that
users register at least 15 minutes prior to the start time.
An archived version of the webcast will be available for replay
in the Events & Presentations section of the Media &
Investors page of Albireo’s website for 3 months following the
event.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat (A4250), is being developed to treat
rare pediatric cholestatic liver diseases and is in Phase 3
development in its initial target indication, progressive familial
intrahepatic cholestasis. Albireo’s clinical pipeline also includes
two Phase 2 product candidates. Elobixibat is in Phase 2
development in NAFLD/NASH. Approved in Japan for the
treatment of chronic constipation, elobixibat is the
first ileal bile acid transporter (IBAT) inhibitor approved
anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located in Boston, Mass., and its
key operating subsidiary is located
in Gothenburg, Sweden. The Boston Business Journal named
Albireo one of the 2019 Best Places to Work in Massachusetts. For
more information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC.,
212-915-2568
Media Contact: Heather Anderson, 6 Degrees,
980-938-0260, handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024